First AD

Second AD

VK Gadi, MD, PhD, shares his insights on managing patients with HER2-positive metastatic breast cancer who have progressed on second and third-line treatments.

TKI Regimens and Other Novel Approaches in Later Line Treatment of HER2+ mBC Setting

Video content above is prompted by the following questions:

For patients who progress through multiple HER2-targeted therapies, when would you consider chemotherapy and what specific regimens?

Are there data supporting the use of continuing HER2 blockade with chemotherapy in later lines?

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: HER2+ Breast Cancer

Memorial Sloan Kettering Cancer Center 

Cancer Centers

Partner

University of Illinois Cancer Center

UT Southwestern Harold C. Simmons Comprehensive Cancer Center 

Vijayakrishna Gadi, MD, PhD, shares his insights on managing patients with HER2-positive metastatic breast cancer who have progressed on second and third-line treatments, stressing the potential benefits of incorporating small molecules, tyrosine kinase inhibitors (TKIs), chemotherapy, and enrolling patients in clinical trials to optimize outcomes.